---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-120706"
form_type: "8-K"
ticker: "GUTS"
cik: "0001572616"
company_name: "FRACTYL HEALTH, INC."
filed_at: "2024-11-04T23:59:59+00:00"
generated_at: "2026-05-30T06:02:26.047655+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Fractyl Health nominates RJVA-002 GIP/GLP-1 gene therapy; positive 13-week preclinical data on RJVA-001

## Summary
- Nominated RJVA-002 as first GIP/GLP-1 pancreatic gene therapy lead candidate for obesity.
- RJVA-001 shows sustained weight and blood sugar control at 13 weeks in DIO mice on high-fat diet.
- Over 10% of islet cells expressed GLP-1 after single dose; no safety signals.
- Data independently validated by Dr. Randy Seeley at University of Michigan.
- Fractyl plans to use durable efficacy results for RJVA-001 FIH data package.

## SEC filing metadata
- accession: 0000950170-24-120706
- form_type: 8-K
- ticker: GUTS
- cik: 0001572616
- company_name: FRACTYL HEALTH, INC.
- filed_at: 2024-11-04T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1572616/000095017024120706/0000950170-24-120706-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1572616/000095017024120706/guts-20241104.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-120706
- JSON: https://secwatch.observer/filing/0000950170-24-120706.json
- Plain text: https://secwatch.observer/filing/0000950170-24-120706.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.